Navigation Links
Flagship's Digital Tissue Image Analysis Approach Validated in Assessment of Dystrophin Muscle Biopsies; Findings Published in Archives of Pathology & Laboratory Medicine
Date:9/7/2018

Flagship Biosciences’ MuscleMap algorithm that supports therapeutic development for DMD, a fatal neuromuscular disease, has been validated to be as effective as manual pathology. The study, “Validation of a Muscle-Specific Tissue Image-Analysis Tool for Quantitative Assessment of Dystrophin Staining in Frozen Muscle Biopsies,” was published in the Archives of Pathology & Laboratory Medicine on August 31, 2018. Download the study here: https://bit.ly/2wMyIVb

Duchenne muscular dystrophy (DMD) is a rare, progressive, and fatal neuromuscular disease caused by dystrophin protein loss in muscle. To support investigational treatment approaches, Flagship applied its expertise and proprietary technology in digital tissue image analysis to develop an immunofluorescent scanning and digital image-analysis solution that enables analysis of all muscle fibers within a biopsy section as well as providing data on each individual fiber.

To validate the MuscleMap approach, the study compared high-powered microscopic field total fiber counts and dystrophin-positive fiber counts obtained by trained pathologists to data produced by the MuscleMap algorithm. The authors note that this work is the first to validate immunofluorescent scanning and digital tissue image analysis workflow with the rigor required to support clinical trials.

“These exciting results will support more effective clinical trials for examining myofibers dystrophin expression by driving a greater level of consistency and detail,” says Trevor D. Johnson, Flagship Biosciences CEO. “Flagship is proud to partner with pharmaceutical and biotech companies in the development of digital image analysis solutions, like MuscleMap, that support the treatment of challenging medical conditions such as DMD.”

Download the study here: https://bit.ly/2wMyIVb

About Flagship Biosciences
Flagship Biosciences Inc. delivers comprehensive tissue profiling for predictive diagnostics in drug therapy using an Artificial Intelligence (AI) enabled computational tissue analysis (cTA®) pathology analytics platform. Our intuitive data reporting gives researchers, clinicians, and drug developers the actionable information needed to drive better clinical results for patients. For more information on how Flagship accelerates drug development, please visit http://www.flagshipbio.com and follow Flagship on Twitter @FlagshipBio.

Read the full story at https://www.prweb.com/releases/flagship_s_digital_tissue_image_analysis_approach_validated_in_assessment_of_dystrophin_muscle_biopsies_findings_published_in_archives_of_pathology_laboratory_medicine/prweb15739001.htm.


'/>"/>
Source: PRWeb
Copyright©2018 Vocus, Inc.
All rights reserved


Related biology technology :

1. Digital Science & SciBite Join Forces to Harness Big Data for Life Sciences
2. BioTechniques: The International Journal of Life Science Methods Announces the Publication of the March 2013 Digital Edition Now Available Online and in the App Store
3. Simagis Digital Web Pathology Launches Service Provider Network
4. Chemical Publishing Company Partners with Author Cloudware for a Digital eBook Distribution for Water Treatment, Waste Water Treatment, and Cooling Water Treatment Titles
5. New Digital Temperature Controllers with Ramp/Soak Capabilities
6. Three Dispensing Modes Featured in the New Masterflex I/P Digital Brushless Process Drives from Cole-Parmer
7. Bugs eye inspires hemispherical digital camera
8. Digital X-Ray Market worth $4.82 By 2018
9. Simagis Web Pathology Adds Fast Search Capability for Digital Slide Archives
10. Pursuit's Elissa Guerra and Eunjoo Pluenneke to Present on Mobile Strategy at Digital Pharma West Conference
11. Don't Forget the Payer in Your Digital Strategy: What Payers Need and Want from Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/7/2018)... ... , ... Diversified Technologies, Inc. (DTI) has installed a PEF (Pulsed ... Technology and Innovation at ASU. Funded by a USDA NIFA SBIR, the purpose of ... and predator control applications. , Algae ponds get up to 50% consumed by predators ...
(Date:11/5/2018)... ... November 05, 2018 , ... GlycoMark, Inc., the exclusive ... through its website, http://www.glycomark.com , as part of National Diabetes Month. ... via the website in November from 9 a.m. – 5 p.m. ET weekdays ...
(Date:10/31/2018)... , ... October 30, 2018 , ... Rooam , ... launch operations in Chicago this winter. After its acquisition of the Tally payment app, ... transactions and set default tips, Rooam will grow its market share and increase the ...
(Date:10/31/2018)... ST. LOUIS, Mo. (PRWEB) , ... October 30, 2018 , ... ... Consider Corn Challenge contest. The goal of this global competition is to find new ... competition. , In 2017, America’s corn farmers produced 14.6 billion bushels of corn and ...
Breaking Biology Technology:
(Date:11/15/2018)... ... 14, 2018 , ... Researchers from Ambry Genetics (Ambry) ... gene-disease relationships and how it supports medical management decisions at the National Society ... , Ambry has been selected by NSGC to lead a platform presentation ...
(Date:11/13/2018)... LINDA, Calif. (PRWEB) , ... ... ... (HRAM) mass spectrometers (MS) are a class of MS instrumentation with capability ... measuring their accurate masses. Specifically, those coupled to liquid chromatograph (HRAM LC/MS) ...
(Date:11/13/2018)... ... November 12, 2018 , ... ... consulting firm specializing in the life sciences, healthcare, and technology services industries, ... and Compliance. Summerville will be responsible for overseeing CREO’s work with clients ...
Breaking Biology News(10 mins):